UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2022-04, Vol.327 (13), p.1236

2022

Volltextzugriff (PDF)

A phase 1 study in healthy volunteers to investigate the safety, tolerability, and pharmacokinetics of VIR-2482: a monoclonal antibody for the prevention of severe influenza A illness

Antimicrobial agents and chemotherapy, 2024-04, Vol.68 (4), p.e0127323-e0127323

2024

Volltextzugriff (PDF)

Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir

Antimicrobial agents and chemotherapy, 2015-11, Vol.59 (11), p.6922-6929

2015

Volltextzugriff (PDF)

Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation

American journal of transplantation, 2020-06, Vol.20 (6), p.1703-1711

2020

Volltextzugriff (PDF)

A Randomized, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of VIR-2482 in Healthy Adults for Prevention of Influenza A Illness (PENINSULA)

Clinical infectious diseases, 2024-10, Vol.79 (4), p.1054-1061

2024

Volltextzugriff (PDF)

Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1

The Journal of experimental medicine, 2009-05, Vol.206 (5), p.1117-1134

2009

Volltextzugriff (PDF)

Effect of Bamlanivimab as Monotherapy or in Combination with Etesevimab or Sotrovimab on Persistently High Viral Load in Patients with Mild-to-Moderate COVID-19: A Randomized, Phase 2 BLAZE-4 Trial

Infectious diseases and therapy, 2024-02, Vol.13 (2), p.401-411

2024

Volltextzugriff (PDF)

Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys

Science translational medicine, 2011-05, Vol.3 (81), p.81ra36

2011

Volltextzugriff (PDF)

Pharmacokinetic Interactions Between Elbasvir/Grazoprevir and Immunosuppressant Drugs in Healthy Volunteers

Journal of clinical pharmacology, 2018-05, Vol.58 (5), p.666-673

2018

Volltextzugriff (PDF)

Efficiency of Cell-Free and Cell-Associated Virus in Mucosal Transmission of Human Immunodeficiency Virus Type 1 and Simian Immunodeficiency Virus

Journal of Virology, 2013-12, Vol.87 (24), p.13589-13597

2013

Volltextzugriff (PDF)

Emergence of a Clinical Daptomycin-Resistant Staphylococcus aureus Isolate during Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia and Osteomyelitis

Journal of Clinical Microbiology, 2006-02, Vol.44 (2), p.595-597

2006

Volltextzugriff (PDF)

Population pharmacokinetics and exposure‐response analysis of a single dose of sotrovimab in the early treatment of patients with mild to moderate COVID‐19

CPT: pharmacometrics and systems pharmacology, 2023-06, Vol.12 (6), p.853-864

2023

Volltextzugriff (PDF)

Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the USA

Infectious diseases and therapy, 2023-02, Vol.12 (2), p.607-621

2023

Volltextzugriff (PDF)

Effect of Hepatic Impairment on the Pharmacokinetics of Grazoprevir, a Hepatitis C Virus Protease Inhibitor

Antimicrobial agents and chemotherapy, 2017-12, Vol.61 (12)

2017

Volltextzugriff (PDF)

Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment

European journal of clinical pharmacology, 2019-05, Vol.75 (5), p.665-675

2019

Volltextzugriff (PDF)

Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravir

Journal of antimicrobial chemotherapy, 2019-03, Vol.74 (3), p.710-717

2019

Volltextzugriff (PDF)

Corrigendum to “A Phase I, Single- and Multiple-dose Study to Evaluate the Pharmacokinetics of Elbasvir and Grazoprevir in Healthy Chinese Participants” [Clinical Therapeutics 40 (2018) 719–732]

Clinical therapeutics, 2018-09, Vol.40 (9), p.1618-1618

2018

Volltextzugriff (PDF)

Virus Inhibition Activity of Effector Memory CD8+ T Cells Determines Simian Immunodeficiency Virus Load in Vaccinated Monkeys after Vaccine Breakthrough Infection

Journal of Virology, 2012-05, Vol.86 (10), p.5877-5884

2012

Volltextzugriff (PDF)

Evaluation of Pharmacokinetic Drug Interactions of the Direct-Acting Antiviral Agents Elbasvir and Grazoprevir with Pitavastatin, Rosuvastatin, Pravastatin, and Atorvastatin in Healthy Adults

Clinical drug investigation, 2021-02, Vol.41 (2), p.133-147

2021

Volltextzugriff (PDF)

Intramuscular vs Intravenous SARS-CoV-2 Neutralizing Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomized Noninferiority Clinical Trial

Open forum infectious diseases, 2023-08, Vol.10 (8), p.ofad354-ofad354

2023

Volltextzugriff (PDF)

A Phase I, Single- and Multiple-dose Study to Evaluate the Pharmacokinetics of Elbasvir and Grazoprevir in Healthy Chinese Participants

Clinical therapeutics, 2018-05, Vol.40 (5), p.719-732.e1

2018

Volltextzugriff (PDF)

Efficacy and safety of a two‐drug direct‐acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6

Journal of viral hepatitis, 2019-09, Vol.26 (9), p.1127-1138

2019

Volltextzugriff (PDF)

Recovery of Herbaspirillum Species from Persons with Cystic Fibrosis

Journal of Clinical Microbiology, 2008-08, Vol.46 (8), p.2774-2777

2008

Volltextzugriff (PDF)

The TRIM5 Gene Modulates Penile Mucosal Acquisition of Simian Immunodeficiency Virus in Rhesus Monkeys

Journal of Virology, 2011-10, Vol.85 (19), p.10389-10398

2011

Volltextzugriff (PDF)

1 – 25 von 166

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(162)
Mit Volltextzugriff
(143)

Publikationsform

Artikel
(165)
Buchkapitel
(1)

Sprache

Englisch
(166)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(112)
Science & Technology
(112)
Humans
(74)
Female
(35)
Male
(32)
Adult
(29)
Animals
(22)
Middle Aged
(22)
Microbiology
(21)
Biological And Medical Sciences
(18)
Pharmacology & Pharmacy
(18)
Virology
(18)
Pediatrics
(17)
Fundamental And Applied Biological Sciences. Psychology
(14)
Child
(13)
Infectious Diseases
(13)
Immunology
(12)
Macaca Mulatta
(12)
Miscellaneous
(12)
Aged
(11)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial

A phase 1 study in healthy volunteers to investigate the safety, tolerability, and pharmacokinetics of VIR-2482: a monoclonal antibody for the prevention of severe influenza A illness

Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir

Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation

A Randomized, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of VIR-2482 in Healthy Adults for Prevention of Influenza A Illness (PENINSULA)

Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1

Effect of Bamlanivimab as Monotherapy or in Combination with Etesevimab or Sotrovimab on Persistently High Viral Load in Patients with Mild-to-Moderate COVID-19: A Randomized, Phase 2 BLAZE-4 Trial

Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys

Pharmacokinetic Interactions Between Elbasvir/Grazoprevir and Immunosuppressant Drugs in Healthy Volunteers

Efficiency of Cell-Free and Cell-Associated Virus in Mucosal Transmission of Human Immunodeficiency Virus Type 1 and Simian Immunodeficiency Virus

Emergence of a Clinical Daptomycin-Resistant Staphylococcus aureus Isolate during Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia and Osteomyelitis

Population pharmacokinetics and exposure‐response analysis of a single dose of sotrovimab in the early treatment of patients with mild to moderate COVID‐19

Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers

Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the USA

Effect of Hepatic Impairment on the Pharmacokinetics of Grazoprevir, a Hepatitis C Virus Protease Inhibitor

Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment

Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravir

Corrigendum to “A Phase I, Single- and Multiple-dose Study to Evaluate the Pharmacokinetics of Elbasvir and Grazoprevir in Healthy Chinese Participants” [Clinical Therapeutics 40 (2018) 719–732]

Virus Inhibition Activity of Effector Memory CD8+ T Cells Determines Simian Immunodeficiency Virus Load in Vaccinated Monkeys after Vaccine Breakthrough Infection

Evaluation of Pharmacokinetic Drug Interactions of the Direct-Acting Antiviral Agents Elbasvir and Grazoprevir with Pitavastatin, Rosuvastatin, Pravastatin, and Atorvastatin in Healthy Adults

Intramuscular vs Intravenous SARS-CoV-2 Neutralizing Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomized Noninferiority Clinical Trial

A Phase I, Single- and Multiple-dose Study to Evaluate the Pharmacokinetics of Elbasvir and Grazoprevir in Healthy Chinese Participants

Efficacy and safety of a two‐drug direct‐acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6

Recovery of Herbaspirillum Species from Persons with Cystic Fibrosis

The TRIM5 Gene Modulates Penile Mucosal Acquisition of Simian Immunodeficiency Virus in Rhesus Monkeys

Suchergebnisse filtern